Synthesis and Molecular Docking Analysis of New Thiazo-isoindolinedione Hybrids as Potential Inhibitors of the SARS-CoV-2 Main Protease-Reference-Cited by-同舟云学术

Synthesis and Molecular Docking Analysis of New Thiazo-isoindolinedione Hybrids as Potential Inhibitors of the SARS-CoV-2 Main Protease

Published:2023-08-30 Issue:4 Volume:39 Page:913-918
ISSN:2231-5039
Container-title:Oriental Journal Of Chemistry
language:en
Short-container-title:Orient. J. Chem

Author:

Shaaban Saad¹^ORCID,Al-Karmalawy Ahmed A.²^ORCID,G. Alhamzani Abdulrahman³^ORCID,Abou–Krisha Mortaga M.⁴^ORCID,Al–Qudah Mahmoud A.³^ORCID,Yousef Tarek A.⁵^ORCID

Affiliation:

1. 1Department of Chemistry, College of Science, King Faisal University, Al–Ahsa 31982, Saudi Arabia.

2. 3Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, 6th of October City, Giza 12566, Egypt.

3. 4College of Science, Chemistry Department, Imam Mohammad Ibn Saud Islamic University, Riyadh 11623, Saudi Arabia.

4. 5Department of Chemistry, Faculty of Science, Yarmouk University, P.O. Box 566, Irbid 21163, Jordan.

5. 7Department of Toxic and Narcotic Drug, Forensic Medicine, Mansoura Laboratory, Medicolegal Organization, Ministry of Justice, Egypt.

Abstract

Herein, we report the synthesis of novel thiazo-isoindolinedione derivatives in excellent yields (up to 92%) from the reaction of thiazolidinedione and isoindoline-dione. The structures of the novel compounds were elucidated by 1H-, 13C-NMR, and MS analyses. Furthermore, molecular docking analysis was performed to study the potential inhibition of the SARS-CoV-2 main protease (Mpro) by the new thiazo-isoindolinediones. The present study revealed that the new thiazo-isoindolinediones could inhibit the Mpro and represent a promising platform for the experimental development of new antiviral drugs based on thiazo-isoindolinedione scaffolds.

Publisher

Oriental Scientific Publishing Company

Subject

Drug Discovery,Environmental Chemistry,Biochemistry,General Chemistry

Reference30 articles.

1. 1. Sies, H.; Parnham, M. J., Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections. Free Radical Biology and Medicine 2020, 156 (20), 107-112

2. 2. Sanders, J. M.; Monogue, M. L.; Jodlowski, T. Z.; Cutrell, J. B., Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. Jama 2020, 323 (18), 1824-1836.

3. 3. Li, Q.; Kang, C., Progress in developing inhibitors of SARS-CoV-2 3C-like protease. Microorganisms 2020, 8 (8), 1250.

4. 4. Houchi, S.; Messasma, Z., Exploring the inhibitory potential of Saussurea costus and Saussurea involucrata phytoconstituents against the Spike glycoprotein receptor binding domain of SARS-CoV-2 Delta (B. 1.617. 2) variant and the main protease (Mpro) as therapeutic candidates, using Molecular docking, DFT, and ADME/Tox studies. Journal of Molecular Structure 2022, 1263, 133032.

5. 5. Amporndanai, K.; Meng, X.; Shang, W.; Jin, Z.; Rogers, M.; Zhao, Y.; Rao, Z.; Liu, Z.-J.; Yang, H.; Zhang, L., Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. Nature communications 2021, 12 (1), 1-7.